Provided By GlobeNewswire
Last update: Jan 21, 2025
TUSTIN, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that leading independent proxy advisory firms Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”) recommend that Avid stockholders vote “FOR” the Company’s pending transaction with GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”).
Read more at globenewswire.com